3 Stocks Advancing The Health Care Sector

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 175 points (-1.2%) at 14,582 as of Wednesday, April 17, 2013, 12:45 PM ET. The NYSE advances/declines ratio sits at 512 issues advancing vs. 2,465 declining with 93 unchanged.

The Health Care sector currently sits down 1.45 versus the S&P 500, which is down 1.75. On the negative front, top decliners within the sector include Sanofi ( SNY), down 3.81, Regeneron Pharmaceuticals ( REGN), down 3.15, Novartis ( NVS), down 2.67, Amgen ( AMGN), down 2.05 and Novo Nordisk A/S ( NVO), down 1.73.

TheStreet Ratings group would like to highlight 3 stocks pushing the sector higher today:

3. Alkermes ( ALKS) is one of the companies pushing the Health Care sector higher today. As of noon trading, Alkermes is up $3.84 (15.00) to $29.44 on heavy volume Thus far, 4.3 million shares of Alkermes exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $27.48-$29.75 after having opened the day at $28.19 as compared to the previous trading day's close of $25.60.

Alkermes Public Limited Company, an integrated biopharmaceutical company, develops medicines that enhance patient outcomes. Alkermes has a market cap of $3.3 billion and is part of the drugs industry. Shares are up 30.8% year to date as of the close of trading on Tuesday.

TheStreet Ratings rates Alkermes as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, compelling growth in net income and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Alkermes Ratings Report now.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.

If you liked this article you might like

The 6 Medications Being Used to Tackle the Opioid Epidemic

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Making Sense of Thursday's Flood of Biotech and Pharma Earnings Reports

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round